p. J. VEITH, S. B, P. SINHA, S. S. SIEGELMAN AND J. W. C. HAGSTROM 
445 
Dr. Moss : I meant, that the initial resistance 
you had, which appeared to be the same as 
when you started, in actuality was higher than 
it would have been in the normal lung because 
normal resistance would have fallen under the 
increased flow. 
Dr. Veith : Right. I understand what you're 
saying. The point is that the animal that re- 
ceived a transplant behaved identically to the 
normal dog. 
Questioner (unidentified) : Do you really 
need to use Imuran? 
Dr. Veith : We've been using a combination 
of Imuran, ALS, and steroids, and although our 
figures are not statistically significant, it ap- 
pears that the animals who received no predni- 
sone and lower doses of Imuran and ALS did 
the best. It may just have been luck and a com- 
bination of other factors. I'm intrigued by your 
observation that you don't need the Imuran. 
Mike Peter, Harbor General Hospital: 
What kind of problems are you having with 
infection? Do you recognize and treat it? 
What per cent mortality is related to infec- 
tion? 
Dr. Veith : I'd have to look at our exact fig- 
ures. A moderate number of the animals de- 
velop pneumonia, which is seen histologically in 
the allografted lungs. Pneumonia often occurs 
in conjunction with rejection, and I'm not sure 
which comes first. I actually think that the re- 
jection comes first, and we have a number of 
studies on our own patients and on histologic 
sections from other patients that point to the un- 
usual forms rejection may take in the lung. This 
is a controversial issue but it appears that in our 
patients, at least, rejection is identifiable and re- 
versible, and has now been distinguished from 
infection with reasonable accuracy in two pa- 
tients. It also appears that what one sees on the 
x-ray as either infection or rejection is most 
often rejection. 
Dr. Peter: Can you reverse rejection in 
dogs? 
Dr. Veith : The appropriate study is now in 
progress, but we certainly think we can do it in 
man. 
